Sandeep Gupta

US Patent:

20030039949, Feb 27, 2003

Filed:

Apr 19, 2002

Appl. No.:

10/125890

Inventors:

David Cappellucci - Wayland MA, US
Kirby Mansfield - Pepperell MA, US
Sandeep Gupta - Somerville MA, US

International Classification:

G09B007/00

US Classification:

434/362000

Abstract:

The present invention is directed to a scalable method and system for efficiently correlating large volumes of information resources. In an e-learning system many large and disparate of educational information resources can be combined and accessed quickly and efficiently. The system made very scalable by the use of central database of learning objectives referred to as a set of Master Learning Objectives or MLOs. Each information object and element of each information resource can be correlated to one or more MLOs in order to establish a link or relationship between the information object or element and the MLO. Once an information object or element is linked to an MLO, additional information objects and elements corresponding to the same subject as the first information object or element can be located by searching for all other information objects and elements linked to the same MLO. In addition, the MLOs can be hierarchically arranged in tree structure in order to further facilitate identifying information objects and elements that correspond to a given MLO or subset of MLOs.

US Patent:

20030078934, Apr 24, 2003

Filed:

Apr 19, 2002

Appl. No.:

10/125891

Inventors:

David Cappellucci - Wayland MA, US
Kirby Mansfield - Pepperell MA, US
Sandeep Gupta - Somerville MA, US

International Classification:

G06F007/00

US Classification:

707/101000

Abstract:

The present invention is directed to a scalable method and system for providing large groups of users with access to a large group of disparate information resources. The system is highly scalable and provide for a layered architecture that enables rapid application development, high availability and strong system security. The method and system can also provide the ability to customize the information provided by allowing the user to locate, assemble, format and combine information elements from diverse information resources in real time.

US Patent:

20050014743, Jan 20, 2005

Filed:

May 27, 2004

Appl. No.:

10/857597

Inventors:

Sandeep Gupta - Plainsboro NJ, US
Gary Samoriski - Hillsborough NJ, US

Assignee:

Forest Laboratories, Inc. - New York NY

International Classification:

A61K031/551
A61K031/343

US Classification:

514220000, 514469000

Abstract:

The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.

US Patent:

20050113458, May 26, 2005

Filed:

Oct 22, 2004

Appl. No.:

10/971306

Inventors:

Sandeep Gupta - Plainsboro NJ, US
Pradeep Banerjee - Hillsborough NJ, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US

Assignee:

Forest Laboratories, Inc. - New York NY

International Classification:

A61K031/13

US Classification:

514659000

Abstract:

The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic Aβ peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic Aβ peptides.

US Patent:

20100076073, Mar 25, 2010

Filed:

Nov 20, 2009

Appl. No.:

12/592171

Inventors:

Sandeep Gupta - Plainsboro NJ, US
Gary Samoriski - Hisslborough NJ, US

Assignee:

MERZ PHARMA GmbH & CO. KGaA - Frankfurt am Main

International Classification:

A61K 31/13
A61K 31/343
A61P 25/24

US Classification:

514469, 514579

Abstract:

The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.

US Patent:

20100273776, Oct 28, 2010

Filed:

Mar 29, 2007

Appl. No.:

12/294893

Inventors:

Susan L. Lindquist - Chestnut Hill MA, US
Tiago Outeiro - Cambridge MA, US
James Fleming - Somerville MA, US
Christine Ellen Bulawa - Arlington MA, US
Charlotte Weigel - Melrose MA, US
Feng Liang - Sudbury MA, US
Sandeep Gupta - Concord OH, US
Amy Ripka - Winthrop MA, US

Assignee:

FOLDRx PHARMACEUTICALS, INC - Cambridge MA
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH - Cambridge MA

International Classification:

A61K 31/519
A61K 31/4045
A61K 31/416
A61K 31/454
A61K 31/445
A61K 31/435
A61K 31/55
C07D 487/04
C07D 209/14
C07D 231/56
C07D 471/04
A61P 43/00
A61P 25/16
A61P 25/28
C12N 5/07

US Classification:

514215, 5142621, 514415, 514406, 514303, 514319, 514297, 544262, 548511, 5483611, 546119, 546120, 544280, 435375

Abstract:

Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease.

US Patent:

20190070182, Mar 7, 2019

Filed:

Nov 2, 2018

Appl. No.:

16/179274

Inventors:

- Lawrenceville NJ, US
Sandeep Gupta - Plainsboro NJ, US
Roger Astbury Smith - Chester Springs PA, US

International Classification:

A61K 31/519
A61K 31/675
A61K 31/541
A61K 9/00
A61K 31/551
A61K 31/55
A61K 31/5377

Abstract:

Disclosed are methods of treating cancer, which include administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof.Also disclosed are methods of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which include contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells. Further disclosed are methods of inhibiting tumor growth, which include contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.

US Patent:

20190008868, Jan 10, 2019

Filed:

Apr 30, 2018

Appl. No.:

15/966436

Inventors:

- Lawrenceville NJ, US
Paras Jariwala - Somerset NJ, US
Wantanee Phuapradit - Montville NJ, US
David Zammit - Fort Lee NJ, US
Louis Denis - Princeton NJ, US
Niranjan Rao - Montgomery NJ, US
Helen Usansky - Hillsborough NJ, US
Sandeep Gupta - Plainsboro NJ, US

International Classification:

A61K 31/519
A61K 9/20
A61P 17/00

Abstract:

Embodiments of the disclosure relate generally to formulations, methods of treatment, kits, and dosage forms for treating inflammatory disorders, including atopic dermatitis, or cancer, the formulations comprising an active pharmaceutical ingredient. The formulation provided comprises granules, wherein the granules comprise: micronized active ingredient; one or more granulation binders; one or more fillers; one or more disintegrants; and one or more antioxidants. In one embodiment, the methods of treatment include orally administering the active ingredient to a subject suffering from atopic dermatitis, where the active ingredient is in an amount of about 20 mg to about 80 mg.